Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma
The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.
You may also be interested in...
Amazon's recent partnership with the Arcadia Group to supply blood glucose strips and meters under the new brand name Choice is another move by the retail giant to disrupt the health-care sector using the path of least resistance.
It is hard not to get caught up in the excitement of reinventing health care deliver amid the wave of retail, PBM and insurer merger agreements and rumors. But there is an immediate impact that might be overlooked: the Medicare Part D market is going to be much more consolidated.
Oncology stars Darzalex and Imbruvica lift a strong fourth quarter, but Remicade biosimilars and pricing discounts continue to threaten to take a bite out of future performance. Tax reform and Amazon's potential entry into healthcare could also affect the diversified firm.